Jens J. Holst
Endocrinology, Diabetes and Metabolism · 2001–2017
A researcher in the Science corpus: 12 papers; trusts 1 researcher and is trusted by 9 researchers here, as inferred from the citation graph.
Subfields
- Endocrinology, Diabetes and Metabolism — 76 citations into it; #44 of 623 by trust here, #96 by citations
- Molecular Biology — 73 citations into it; #11,122 of 17,773 by trust here, #7,747 by citations
- Surgery — 41 citations into it; #117 of 1,106 by trust here, #280 by citations
Whom Jens J. Holst trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Jens J. Holst overall
Papers from Jens J. Holst's perspective
Ordered by how strongly the researchers Jens J. Holst trusts endorse each paper. Same corpus, a different order for every researcher.
- Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. (Diabetes)
- Glucagon-like peptide-1 receptor is involved in learning and neuroprotection (Nature Medicine)
- Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes (Nature Genetics)
- Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. (Diabetes)
- Pioglitazone for diabetes prevention in impaired glucose tolerance. (New England Journal of Medicine)
- Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care
- The biology of incretin hormones. (Cell Metabolism)
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus (Diabetes)
- An obesity-associated gut microbiome with increased capacity for energy harvest (Nature)
- Fat, Fiber and Cancer Risk in African Americans and Rural Africans (Nature Communications)
Their papers
- Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. (2017) — 907 citations
- The physiology of glucagon-like peptide 1. (2007) — 3,254 citations
- The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. (2003) — 614 citations
- Type 2 diabetes mellitus (2015) — 2,875 citations
- Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. (2006) — 967 citations
- Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. (2004) — 677 citations
- Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. (2004) — 679 citations
- Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. (2002) — 603 citations
- Inhibition of gastric inhibitory polypeptide signaling prevents obesity (2002) — 957 citations
- Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. (2002) — 1,366 citations
- Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. (2001) — 916 citations
- Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. (2001) — 926 citations